Supplementary Figure S3 from Chemoimmunotherapy Outcomes and Prognostic Factors in Patients with Advanced, Low PD-L1–Expressing Non–Small Cell Lung Cancer
Research reveals adverse events like interstitial pneumonitis in patients with low PD-L1 non-small cell lung cancer, highlighting the significance of treatment outcomes.
Key Points
MAIN FINDING: Chemoimmunotherapy can lead to adverse events such as interstitial pneumonitis in low PD-L1 expressing patients.
KEY EVIDENCE: Adverse events were observed in clinical settings, underscoring risks associated with treatment outcomes.
APPROACH: The study examined patient data to evaluate the incidence of adverse events in a specific lung cancer population.
SIGNIFICANCE: Understanding prognostic factors and adverse events can improve treatment strategies for patients with this cancer type.